1. MG53 promotes corneal wound healing and mitigates fibrotic remodeling in rodents.
- Author
-
Chandler HL, Tan T, Yang C, Gemensky-Metzler AJ, Wehrman RF, Jiang Q, Peterson CMW, Geng B, Zhou X, Wang Q, Kaili D, Adesanya TMA, Yi F, Zhu H, and Ma J
- Subjects
- Animals, Cell Movement drug effects, Cell Movement genetics, Cornea drug effects, Cornea pathology, Corneal Injuries metabolism, Corneal Injuries physiopathology, Epithelium, Corneal drug effects, Epithelium, Corneal metabolism, Fibroblasts cytology, Fibroblasts drug effects, Fibroblasts metabolism, Fibrosis, Humans, Membrane Proteins metabolism, Mice, Knockout, Rats, Recombinant Proteins pharmacology, Regeneration drug effects, Regeneration genetics, Rodentia genetics, Rodentia metabolism, Transforming Growth Factor beta pharmacology, Wound Healing drug effects, Wound Healing physiology, Cornea metabolism, Corneal Injuries genetics, Membrane Proteins genetics, Wound Healing genetics
- Abstract
The cornea plays an important role in transmitting light and providing protection to the eye, but is susceptible to injury and infection. Standard treatments for corneal wounds include topical lubricants, antibiotics, bandage contact lens, and surgery. However, these measures are often ineffective. Here we show that MG53, a protein with an essential role in cell membrane repair, contributes to the corneal injury-repair process. Native MG53 is present in the corneal epithelia, tear film, and aqueous humor, suggesting its potential function in corneal homeostasis. Knockout of MG53 in mice causes impaired healing and regenerative capacity following injury. Exogenous recombinant human MG53 (rhMG53) protein protects the corneal epithelia against mechanical injury and enhances healing by promoting migration of corneal fibroblasts. Using in vivo alkaline-induced injury to the rat cornea, we show that rhMG53 promotes re-epithelialization and reduces post-injury fibrosis and vascularization. Finally, we show that rhMG53 modulates TGF-β-mediated fibrotic remodeling associated with corneal injury. Overall, our data support the bi-functional role of MG53 in facilitating corneal healing and maintaining corneal transparency by reducing fibrosis and vascularization associated with corneal injuries., Competing Interests: J.M. is a founder of TRIM-edicine, Inc. and T.T. has an equity interest in TRIM-edicine, Inc., a biotechnology company developing rhMG53 as a therapeutic protein. The remaining authors declare no competing interests.
- Published
- 2019
- Full Text
- View/download PDF